Mouse Genetics Facility

小鼠遗传学设施成立于 1999 年，以满足癌症中心日益增长的需求 研究人员分析小鼠模型中的基因功能，并自此以来一直得到癌症中心的支持 2002 年。自上次更新以来，该机构领导层发生了变化，安东尼·卡波比安科 (Anthony Capobianco) 博士现在担任 该设施的科学主任和设施主任蒋平博士。在本次资助期间，研究所 已投资 167,450 美元购买新设备和升级设备以及翻新实验室和动物设施空间。 该设施可高效生产转基因小鼠和基因敲除/敲入 (KO/KI) 小鼠，此外 它在胚胎干（ES）细胞培养和工程方面提供独特的资源和专业知识， 使癌症中心的研究人员能够生成体内和体外的小鼠癌症模型。当前 服务与癌症中心计划的研究目标一致，包括：(1) 生产 通过DNA转基因构建体的原核显微注射制备转基因小鼠； (2) 基因靶向的产生 129和C57BL小鼠ES细胞克隆； (3)显微注射衍生嵌合小鼠的产生 将基因靶向的 ES 细胞转化为囊胚； (4)通过胚胎移植重新衍生小鼠品系； (5) ES细胞 栽培和工程。自2006年以来，该设施已培育出15个转基因小鼠品系，并成功 产生11系KO/KI小鼠ES细胞克隆，并产生8系嵌合KO/KI小鼠。此外， 该设施成功地重新衍生了一个工程小鼠品系，并将提供小鼠胚胎 2008 年开始提供冷冻保存服务。该设施正在与癌症中心研究人员积极合作， 利用其小鼠 ES 细胞技术，旨在利用人类 ES 细胞作为载体来衍生突变体或 疾病特异性细胞谱系作为新的人类疾病模型系统。该设施未来的目标 资助期包括为一些困难的小鼠品系开发慢病毒介导的转基因技术 通过 DNA 显微注射进行生产，开发使用四倍体互补作为一种有效的方法 将 C57BL 来源的 ES 细胞注射到囊胚中产生嵌合体，并建立人 ES 细胞培养和工程作为常规服务。

The Mouse Genetics Facility was established in 1999 in response to the increasing need of Cancer Center investigators for analysis of gene function in mouse models, and has received Cancer Center support since 2002. Since the last renewal, the Facility has changed leadership, with Dr. Anthony Capobianco now the scientific director of the Facility and Dr. Ping Jiang the facility director. In this funding period, the Institute has invested $167,450 for new and upgraded equipment and renovated laboratory and animal facility space. The Facility provides highly efficient production of both transgenic and knock-out/knock-in (KO/KI) mice, plus it provides a unique resource and expertise in embryonic stem (ES) cell cultivation and engineering, which benefits Cancer Center investigators generating both in vivo and in vitro murine models of cancer. Current services are aligned with the research objectives of the Cancer Center programs and include: (1) production of transgenic mice by pronuclear microinjection of DNA transgene constructs; (2) generation of genetargeted 129 and C57BL mouse ES cell clones; (3) production of chimeric mice derived from microinjection of gene-targeted ES cells into blastocysts; (4) rederivation of mouse lines by embryo transfer; and (5) ES cell cultivation and engineering. Since 2006, the Facility has produced 15 lines of transgenic mice, successfully generated 11 lines of KO/KI mouse ES cell clones, and produced 8 lines of chimeric KO/KI mice. In addition, the Facility successfully rederived a line of an engineered mouse strain and will offer a mouse embryo cryopreservation service in 2008. The Facility is actively collaborating with Cancer Center investigators to utilize its mouse ES cell technology, with the aim of using human ES cells as a vehicle to derive mutant or disease specific cell lineages as a new human disease model system. Goals for the Facility over the next funding period include developing lentiviral mediated transgenesis for some strains of mice that are difficult to produce with DNA microinjection, developing use of tetraploid complementation as an efficient approach to produce chimeras from injections of ES cells of C57BL origin into blastocysts, and establishing human ES cell cultivation and engineering as a routine service.